Overview

Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:
0

Participant gender:
All

Summary

Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing dialysis, the risk of dying is very high.There are no known therapies to reduce the chance of developing kidney damage after heart surgery. There is evidence that patients with high levels of a substance called ouabain have an increased risk of developing kidney damage. This study is testing the hypothesis that giving a medication called DigiFab to lower the ouabain levels will reduce the risk of developing kidney damage after heart surgery.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Maryland
University of Maryland, Baltimore

Treatments:

Antibodies
Digoxin
Immunoglobulin Fab Fragments
Immunoglobulins
Ouabain

Criteria

Inclusion Criteria:

- Undergoing coronary artery bypass surgery

- glomerular filtration rate > 15 History of Diabetes Mellitus or GFR < 60

Exclusion Criteria:

- Allergy to Digifab Contrast dye within 3 days Creatinine > 25% above baseline